普洛药业：与嘉兴安帝康生物科技有限公司签订《战略合作框架协议》

Core Insights - Pro Pharmaceutical Co., Ltd. has signed a strategic cooperation framework agreement with Jiaxing Andikang Biotechnology Co., Ltd. to seek long-term collaboration in innovative drug development, enhancing industry competitiveness and supply stability [1] - The agreement is a framework agreement and does not involve substantial transactions or constitute a related party transaction, nor does it fall under the major asset restructuring regulations [1] - For the first half of 2025, Pro Pharmaceutical's revenue composition is 99.6% from the pharmaceutical industry and 0.4% from other businesses [1] Company Overview - Pro Pharmaceutical's market capitalization is currently 17.5 billion yuan [2]